BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19321281)

  • 1. [Hepatocellular carcinoma management in the era of sorafenib].
    Rosmorduc O
    Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
    [No Abstract]   [Full Text] [Related]  

  • 2. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
    Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
    Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
    Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
    Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib-induced acute pancreatitis.
    Saadati H; Saif MW
    JOP; 2010 May; 11(3):283-4. PubMed ID: 20442531
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    Kelley RK; Venook AP
    J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.
    Di Benedetto F; Tarantino G; Montalti R; Ballarin R; D'Amico G; Berretta M; Gerunda GE
    Transpl Int; 2011 Nov; 24(11):e97; author reply e98-9. PubMed ID: 21910763
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Kuzuya T; Tsuchiya K; Izumi N
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
    Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
    Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closing remarks.
    Kudo M
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():52. PubMed ID: 22873627
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
    Lapecorella M; Napolitano M; Tudini M; Bruera G; Lucchesi A; Giordano AV; Mariani G; Ricevuto E
    Haemophilia; 2010 Jan; 16(1):185-7. PubMed ID: 19804385
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
    Truesdale AE; Caldwell SH; Shah NL; Argo CK; Al-Osaimi AM; Schmitt TM; Northup PG
    Transpl Int; 2011 Oct; 24(10):991-8. PubMed ID: 21777298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug therapy: sorafenib.
    Finn RS
    Hepatology; 2010 May; 51(5):1843-9. PubMed ID: 20432260
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA approves sorafenib for patients with inoperable liver cancer.
    Lang L
    Gastroenterology; 2008 Feb; 134(2):379. PubMed ID: 18242200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.